ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Research Associate II, CRISPR-X - LNP at CRISPR Therapeutics - ApplyBlast

Research Associate II, CRISPR-X - LNP

CRISPR Therapeutics

4 months ago

3.1 on Glassdoor

South Boston, MA

Onsite

Full Time

Senior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

CRISPR Therapeutics is seeking a Research Associate II to design, develop, and optimize lipid nanoparticle (LNP) formulations for non-viral delivery of genome editing therapies. The role involves executing analytical characterization, managing cell culture, and supporting preclinical therapeutic programs with minimal supervision. This position contributes to advancing platform technology and clinical translation within the CRISPR-X division.

Responsibilities

Design and optimize lipid nanoparticle formulations for diverse therapeutic payloads.
Execute analytical characterization using RiboGreen assays, DLS, and NTA techniques.
Perform mammalian cell culture and support in vitro transfection studies.
Generate reproducible datasets and maintain accurate electronic laboratory notebooks.
Collaborate with process development and analytical teams to advance manufacturing processes.

Skills

Qualifications

BS in ChemistryMS in ChemistryBS in Chemical EngineeringBS in BiochemistryResearch Associate II Experience

About CRISPR Therapeutics

crisprtx.com

Headquarters

Boston, Massachusetts, United States

Company Size

201-500 employees

Founded

2013

View Profile

CRISPR Therapeutics is a gene-editing company pioneering the development of transformative medicines using CRISPR/Cas9 technology to treat serious diseases. The company has a broad pipeline spanning hemoglobinopathies, immuno-oncology, autoimmune diseases, in vivo editing, and regenerative medicine, including CASGEVY™, the first-ever approved CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia. CRISPR Therapeutics operates across multiple clinical and preclinical programs in collaboration with partners such as Vertex Pharmaceuticals.